What is NAD+ and why does it decline with age?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for converting nutrients into ATP and activating repair enzymes called sirtuins and PARPs. Tissue NAD+ levels have been shown in multiple animal and human studies to decline significantly with age, with some estimates suggesting a 40-60% reduction between young adulthood and mid-life. This decline is thought to contribute to reduced cellular energy production and impaired DNA repair capacity.

Is NAD+ FDA-approved?

No. NAD+ itself is not approved by the FDA as a pharmaceutical drug for any indication. Oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are sold as dietary supplements and are not FDA-approved drugs either. IV and subcutaneous NAD+ infusions are offered at some clinics under wellness or compounding frameworks, but this use is not FDA-approved and the evidence base is still emerging.

What is the difference between NAD+, NMN, and NR?

NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that cells convert into NAD+. Direct IV or subcutaneous NAD+ bypasses the conversion steps and raises blood NAD+ levels quickly, while oral NMN and NR rely on absorption and enzymatic conversion in tissues, which is slower and less complete.

What does the research say about NAD+ and aging?

Preclinical studies in rodents have shown that raising NAD+ levels can improve mitochondrial function, muscle endurance, metabolic health markers, and lifespan in some models. Early human trials with oral NR and NMN have demonstrated that these precursors raise blood NAD+ levels safely. However, robust, large-scale randomized controlled trials demonstrating clear clinical benefits in humans are still limited as of early 2026, and most findings should be considered preliminary.

What side effects are associated with NAD+ infusions?

IV NAD+ infusions are commonly associated with transient flushing, chest tightness, nausea, and a sense of pressure or discomfort during the infusion, particularly when administered too rapidly. Slowing the infusion rate typically resolves these symptoms. Subcutaneous injections may cause local injection-site reactions. Oral precursors are generally well tolerated, with mild nausea or flushing reported at higher doses. Serious adverse events appear rare in published literature but the long-term safety profile of high-dose supplementation is not fully established.

Can I track NAD+ protocols in Redose?

Yes. Redose supports logging any injectable or infusion protocol, including NAD+. You can set up a custom protocol, track each session with one tap, record the injection site, and monitor your vial inventory so you always know how many doses remain.

NAD+ · Redose

Creator: Redose
Published: 2026-04-02

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the human body, where it serves as an essential electron carrier in energy metabolism and a substrate for a broad family of enzymes involved in DNA repair and gene regulation. Interest in supplementing NAD+ directly, or raising it through precursor compounds, has grown considerably as research has linked declining NAD+ levels to cellular aging, metabolic dysfunction, and reduced resilience to stress. It is not a peptide in the strict sense, but it appears in peptide-therapy clinics and longevity protocols alongside compounds such as BPC-157 and sermorelin, and the same careful tracking principles apply.

What is NAD+

NAD+ exists in two primary redox forms: the oxidized form (NAD+) and the reduced form (NADH). Together they shuttle electrons through the mitochondrial electron transport chain, enabling cells to generate ATP from glucose, fatty acids, and amino acids. Beyond energy production, NAD+ is the required substrate for sirtuins (SIRT1-SIRT7), a family of deacetylase enzymes that regulate gene expression, mitochondrial biogenesis, inflammation, and circadian rhythms. It is also consumed by PARP enzymes that repair damaged DNA strands.

Tissue NAD+ levels decline with age in multiple species, including humans. This decline has been documented in skeletal muscle, liver, brain, and skin. The reasons are multifactorial: increased PARP activity from accumulated DNA damage, shifts in the NAD+ biosynthetic pathway, and reduced expression of key enzymes in the salvage pathway.

How it works

The primary mechanisms attributed to NAD+ replenishment are:

Sirtuin activation. Higher NAD+ availability increases sirtuin activity, which in turn promotes mitochondrial biogenesis (via PGC-1-alpha), reduces inflammatory signaling, and supports metabolic flexibility.
PARP support. Adequate NAD+ ensures that PARP-mediated DNA repair can proceed without depleting the coenzyme pool, which would otherwise impair other NAD+-dependent processes.
Mitochondrial efficiency. Restoring NAD+ in aged or stressed mitochondria has been shown in animal models to improve oxidative phosphorylation and reduce oxidative stress byproducts.

When NAD+ is administered intravenously, circulating levels rise rapidly. The circulating half-life is approximately 1-2 hours, though intracellular replenishment and the downstream effects on enzyme activity unfold over a longer timeframe. Subcutaneous administration is slower but avoids the infusion-related discomfort associated with IV delivery.

What the research says

Most of the compelling mechanistic data on NAD+ replenishment comes from preclinical (animal) studies. In rodent models, raising NAD+ via NMN or NR has reversed aspects of vascular aging, improved muscle function, enhanced cognitive performance in Alzheimer's models, and extended median lifespan in some strains.

Human clinical data is growing but still limited. Published randomized trials with oral NR and NMN have consistently demonstrated that these precursors raise blood and muscle NAD+ levels safely in healthy adults and older individuals. A 2018 study in Nature Communications (Martens et al.) found that NMN raised blood NAD+ levels dose-dependently in healthy middle-aged and older adults over 10 weeks, with good tolerability. Studies examining functional outcomes such as muscle strength, insulin sensitivity, and cognitive performance have shown mixed or modest results.

Direct IV NAD+ has been used in addiction medicine settings (particularly for opioid and alcohol withdrawal support) with anecdotal reports of reduced cravings and improved mood, but controlled trial data in this area remains sparse. The neurological and neuroprotective applications are considered promising but investigational.

It is important to note that raising blood NAD+ is not the same as demonstrating a specific clinical benefit. The field is active and evolving, and conclusions should be drawn cautiously until larger, well-controlled human trials report outcomes.

Typical dosing

Because NAD+ is not approved as a pharmaceutical, there is no standardized clinical dose. The following ranges are reported in published research, case series, and clinical wellness protocols; they are not a recommendation:

Route	Reported range	Notes
IV infusion	250-1000 mg per session	Typically over 2-4 hours; 500 mg is a common starting point in clinic protocols
Subcutaneous injection	25-100 mg per session	Less studied than IV; lower peak plasma levels
Intranasal	50-200 mg per session (off-label)	Absorption is variable; limited published data
Oral NMN (precursor)	250-1000 mg/day	Multiple published human trials; raises blood NAD+ but conversion efficiency varies
Oral NR (precursor)	250-500 mg/day	Well-studied precursor; FDA GRAS-notified as a food ingredient

Dosing frequency for IV protocols in longevity contexts ranges from a single loading series (daily infusions for 4-10 days) to monthly maintenance sessions. Protocols vary widely across providers. A qualified healthcare provider should guide any injectable or infusion protocol, taking into account individual health status, concurrent medications, and monitoring parameters.

Dosing information above reflects ranges reported in research literature and clinical protocols. It is not medical advice and should not be used to self-prescribe.

Side effects and safety

NAD+ has a generally favorable short-term safety profile in published studies, particularly for oral precursors. Key considerations include:

IV infusion reactions. Flushing, warmth, chest tightness, nausea, and palpitations are common during IV administration if the rate is too fast. These symptoms are typically transient and resolve by reducing the infusion rate or pausing the drip. They are not considered allergic reactions in most cases.
Subcutaneous site reactions. Redness, swelling, or mild pain at the injection site can occur.
Oral precursors. NR and NMN are generally well tolerated. Mild GI upset, flushing, and fatigue have been reported at high doses. No serious adverse events have been identified in published trials to date.
Drug interactions. NAD+ metabolism intersects with several enzymatic pathways. Patients taking chemotherapy agents, immunosuppressants, or medications metabolized by sirtuin-related pathways should discuss NAD+ supplementation with their prescribing physician.
Long-term safety. Multi-year safety data for high-dose IV or subcutaneous NAD+ supplementation is not yet available. The field is moving quickly, and safety guidance may evolve.

Anyone with a cardiovascular condition, active cancer, or complex medical history should obtain medical clearance before starting any NAD+ protocol.

Tracking NAD+ with Redose

Consistency matters in any longevity protocol, and NAD+ infusion or injection schedules are no exception. Redose (available at /#download) lets you build a custom NAD+ protocol, log each session with a single tap, and track your vial inventory so you always know how many doses remain before your next order. The built-in dose calculator handles reconstitution math if you are working with lyophilized powder, and injection-site rotation logging helps you maintain a rotation log across sessions. Whether you are on a weekly maintenance schedule or an intensive loading series, Redose keeps the record-keeping out of the way so you can focus on your protocol.

This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.

NAD+